The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition
Open accessAbstract
Background: Inflammatory responses play a multiphase role in the pathogenesis of cerebral ischemic stroke (IS). Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway. Based on its anti-inflammatory and immunosuppressive effects, we hypothesized that it may have a protective effect against stroke. The aim of this study was to investigate whether inhibition of JAK2 has a neuroprotective effect on ischemic stroke and to explore the potential molecular mechanisms. Methods: Rux, MCC950 or vehicle was applied to middle cerebral artery occlusion (MCAO) mice in vivo and an oxygen-glucose deprivation/reoxygenation (OGD/R) model in vitro. After 3 days of reperfusion, neurological deficit scores, infarct volume and brain water content were assessed. Immunofluorescence staining and western blots were used to measure the expression of NLRP3 inflammasome components. The infiltrating cells were investigated by flow cytometry. Proinflammatory cytokines were assessed by RT-qPCR. The expression of the JAK2/STAT3 pathway was measured by western blots. Local STAT3 deficiency in brain tissue was established with a lentiviral vector carrying STAT3 shRNA, and chromatin immunoprecipitation (ChIP) assays were used to investigate the interplay between NLRP3 and STAT3 signaling. Results: Rux treatment improved neurological scores, decreased the infarct size and ameliorated cerebral edema 3 days after stroke. In addition, immunofluorescence staining and western blots showed that Rux application inhibited the expression of proteins related to the NLRP3 inflammasome and phosphorylated STAT3 (P-STAT3) in neurons and microglia/macrophages. Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-α, IFN-γ, HMGB1, IL-1β, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation. Infiltrating macrophages, B, T, cells were also reduced by Rux. Local STAT3 deficiency in brain tissue decreased histone H3 and H4 acetylation on the NLRP3 promoter and NLRP3 inflammasome component expression, indicating that the NLRP3 inflammasome may be directly regulated by STAT3 signaling. Rux application suppressed lipopolysaccharide (LPS)-induced NLRP3 inflammasome secretion and JAK2/STAT3 pathway activation in the OGD/R model in vitro. Conclusion: JAK2 inhibition by Rux in MCAO mice decreased STAT3 phosphorylation, thus inhibiting the expression of downstream proinflammatory cytokines and the acetylation of histones H3 and H4 on the NLRP3 promoter, resulting in the downregulation of NLRP3 inflammasome expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Campbell, B. C. V., De Silva, D. A., Macleod, M. R., Coutts, S. B., Schwamm, L. H., Davis, S. M., & Donnan, G. A. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0118-8 · Cited by 1,750
The inflammatory response in stroke
Wang, Q., Tang, X. N., & Yenari, M. A. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.014 · Cited by 1,177
Interleukin-6, a Major Cytokine in the Central Nervous System
Erta, M., Quintana, A., & Hidalgo, J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4679 · Cited by 1,087
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409002 · Cited by 891
Inflammatory Cytokines in Experimental and Human Stroke
Lambertsen, K. L., Biber, K., & Finsen, B. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.88 · Cited by 732
Bhaskar, S., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J. S., Rajagopal, S., Pai, A. R., & Kutty, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01648 · Cited by 511
Biology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470 · cited 1×
“Other signaling molecules, such as STAT1, STAT3, and STAT5, are also regulated by JAK2 (17).”
BackgroundFranke, M., Bieber, M., Kraft, P., Weber, A. N. R., Stoll, G., & Schuhmann, M. K. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.12.009 · Cited by 382
“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Bousoik, E., & Montazeri Aliabadi, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00287 · Cited by 376
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 373
Das, R., Guan, P., Sprague, L., Verbist, K., Tedrick, P., An, Q. A., Cheng, C., Kurachi, M., Levine, R., Wherry, E. J., et al. (2016) · Blood · doi:10.1182/blood-2015-12-684399 · Cited by 254
Ye, Y., Jin, T., Zhang, X., Zeng, Z., Ye, B., Wang, J., Zhong, Y., Xiong, X., & Gu, L. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00553 · Cited by 238
Self-citationRatajczak, M. Z., & Kucia, M. (2020) · Leukemia · doi:10.1038/s41375-020-0887-9 · Cited by 235
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
La Rosée, F., Bremer, H. C., Gehrke, I., Kehr, A., Hochhaus, A., Birndt, S., Fellhauer, M., Henkes, M., Kumle, B., Russo, S. G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0891-0 · Cited by 231
Severe COVID-19: NLRP3 Inflammasome Dysregulated
van den Berg, D. F., & te Velde, A. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01580 · Cited by 223
Chen, S., Dong, Z., Cheng, M., Zhao, Y., Wang, M., Sai, N., Wang, X., Liu, H., Huang, G., & Zhang, X. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0963-x · Cited by 214
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Elli, E. M., Baratè, C., Mendicino, F., Palandri, F., & Palumbo, G. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01186 · Cited by 207
Al Mamun, A., Chauhan, A., Qi, S., Ngwa, C., Xu, Y., Sharmeen, R., Hazen, A. L., Li, J., Aronowski, J. A., McCullough, L. D., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914742117 · Cited by 189
Ischemic Brain Edema and the Osmotic Gradient between Blood and Brain
Hatashita, S., Hoff, J. T., & Salamat, S. M. (1988) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1988.96 · Cited by 184
Zhou, K., Chen, J., Wu, J., Wu, Q., Jia, C., Xu, Y. X. Z., Chen, L., Tu, W., Yang, G., Kong, J., et al. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152922 · Cited by 162
Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
Hornung, T., Janzen, V., Heidgen, F.-J., Wolf, D. G. F., Bieber, T. R. M., & Wenzel, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1412997 · Cited by 156
Inflammation and myeloproliferative neoplasms
Lussana, F., & Rambaldi, A. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.010 · Cited by 136
Inflammation-Mediated Angiogenesis in Ischemic Stroke
Zhu, H., Zhang, Y., Zhong, Y., Ye, Y., Hu, X., Gu, L., & Xiong, X. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.652647 · Cited by 136
Self-citationRegulation and function of signal transducer and activator of transcription 3
Qi, Q.-R., & Yang, Z.-M. (2014) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v5.i2.231 · Cited by 126
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
Bağca, B. G., & Avcı, Ç. B. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.013 · Cited by 126
Zhong, Y., Yin, B., Ye, Y., Dekhel, O. Y. A. T., Xiong, X., Jian, Z., & Gu, L. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113690 · Cited by 121
Self-citationSexually dimorphic microglia and ischemic stroke
Kerr, N. A., Dietrich, D. W., Bramlett, H. M., & Raval, A. P. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13267 · Cited by 117
STAT3-mediated anti-inflammatory signalling
Murray, P. J. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341028 · Cited by 113
Liu, C., Huang, Z., Li, X., Shen, K., Liu, M., Ouyang, H., Zhang, S., Ruan, Y., Zhang, X., Wu, S.-L., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.01.011 · Cited by 110
Gu, L., Xiong, X., Zhang, H., Xu, B., Steinberg, G. K., & Zhao, H. (2012) · Stroke · doi:10.1161/strokeaha.112.656611 · Cited by 107
Self-citationIL-4 Is Required for Sex Differences in Vulnerability to Focal Ischemia in Mice
Xiong, X., Xu, L., Wei, L., White, R., Ouyang, Y., & Giffard, R. G. (2015) · Stroke · doi:10.1161/strokeaha.115.008897 · Cited by 106
Self-citationGuekht, A. B., Skoog, I. G., Edmundson, S., Zakharov, V. V., & Korczyn, A. D. (2017) · Stroke · doi:10.1161/strokeaha.116.014321 · Cited by 98
Hu, G., Yu, L., Du, X., Li, Y.-J., Gao, X.-Q., & Chen, B.-Q. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.198992 · Cited by 85
Yu, S., Zhao, G., Han, F., Liang, W., Yuan, J., Li, Z., & Li, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106355 · Cited by 78
Tian, Y., Zhong, D., Liu, Q. Q., Zhao, X. L., Sun, H. X., Jin, J., Wang, H. N., & Li, G. Z. (2018) · Journal of neurosurgery · doi:10.3171/2017.5.jns163165 · Cited by 74
Xiong, X., Gu, L., Wang, Y., Luo, Y., Zhang, H., Lee, J., Krams, S. M., Zhu, S., & Zhao, H. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0705-5 · Cited by 71
Self-citationBlood substitution therapy rescues the brain of mice from ischemic damage
Ren, X. S., Hu, H., Farooqi, I., & Simpkins, J. W. (2020) · Nature Communications · doi:10.1038/s41467-020-17930-x · Cited by 69
Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis
Salit, R. B., Scott, B. L., Stevens, E. A., Baker, K. K., Gooley, T. A., & Deeg, H. J. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0523-3 · Cited by 50
Lemarchand, E., Barrington, J., Chenery, A., Haley, M., Coutts, G., Allen, J. E., Allan, S. M., & Brough, D. (2019) · Stroke · doi:10.1161/strokeaha.118.023620 · Cited by 49
Liu, C., Zhao, Q., Zhong, L. X., Li, Q., Li, R., Li, S., Li, Y., Li, N., Su, J., Dhondrup, W., et al. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.113820 · Cited by 38
Self-citationYang, G., Huang, C., Cao, J., Huang, K., Jiang, T., & Qiu, Z. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.3757 · Cited by 29
Ras-Related C3 Botulinum Toxin Substrate 1 Promotes Axonal Regeneration after Stroke in Mice
Liu, L., Yuan, H., Yi, Y., Koellhoffer, E. C., Munshi, Y., Bu, F., Zhang, Y., Zhang, Z., McCullough, L. D., & Li, J. (2018) · Translational Stroke Research · doi:10.1007/s12975-018-0611-5 · Cited by 25
Self-citationFiore, D., Cappelli, L. V., Zumbo, P., Phillip, J. M., Liu, Z., Cheng, S., Yoffe, L., Ghione, P., Maggio, F. D., Doǧan, A., et al. (2020) · Cancers · doi:10.3390/cancers12061603 · Cited by 18
Markotić, A., Flegar, D., Grčević, D., Šućur, A., Lalić, H., Turčić, P., Kovačić, N., Lukac, N., Pravdić, D., Vukojević, K., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14930 · Cited by 16
Sahu, M., & Sahu, A. (2015) · Peptides · doi:10.1016/j.peptides.2015.08.011 · Cited by 11
Cited by
Interleukins and Ischemic Stroke
Zhu, H., Hu, S., Li, Y., Sun, Y., Xiong, X., Hu, X., Chen, J., & Qiu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828447 · Cited by 363
Self-citationPyroptosis in health and disease: mechanisms, regulation and clinical perspective
Liu, Y., Pan, R., Ouyang, Y., Gu, W., Xiao, T., Yang, H., Tang, L., Wang, H., Xiang, B., & Chen, P. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01958-2 · Cited by 337
Jo, S., Baek, A., Cho, Y., Kim, S. H., Baek, D., Hwang, J., Cho, S.-R., & Kim, H. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-32744-9 · Cited by 19
Kang, J., Zhou, Y., Xiong, Q., & Dong, X. (2024) · Aging · doi:10.18632/aging.205795 · Cited by 5
Metadata
- Authors
- Zhu, H., Jian, Z., Zhong, Y., Ye, Y., Zhang, Y., Hu, X., Pu, B., Gu, L., & Xiong, X.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-07-22
- Volume
- 12
- Pages
- 714943-714943
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3134875727
- Cited by
- 370
- References
- 46
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.